Latest news with #BUSINESSWIRE
Business Wire
17 minutes ago
- Business
- Business Wire
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor mesutoclax (ICP-248) in combination with azacitidine for the treatment of myeloid malignancies, including but not limited to myelodysplastic syndromes (MDS). Mesutoclax is an important global asset of InnoCare in the field of hematology. This approval marks the Company will initiate the clinical trial for the fourth indication of our BCL2 inhibitor. Mesutoclax is a novel, orally bioavailable BCL2 selective inhibitor. BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of various hematologic malignancies. Mesutoclax exerts anti-tumor activity by selectively inhibiting BCL2 and restoring the normal apoptosis process in cancer cells. Myelodysplastic syndrome (MDS) is a group of heterogeneous clonal myeloid diseases characterized by the abnormal proliferation of hematopoietic stem cells, recurrent genetic abnormalities, myelodysplasia, ineffective hematopoiesis, peripheral-blood cytopenia, and a high risk of progression to acute myeloid leukemia (AML). The annual incidence of myelodysplastic syndromes is about 4 cases/100,000 people/year (reaching 40–50/100,000 in patients aged ≥ 70 years). Mesutoclax has been granted Breakthrough Therapy Designation (BTD) by the CDE for the treatment of BTKi-treated relapsed or refractory mantle cell lymphoma (R/R MCL). This marks the first BCL2 inhibitor to receive BTD recognition in China. The Company is accelerating patient enrollment of a Phase III registrational trial of mesutoclax in combination with orelabrutinib as a first line therapy for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), as well as a clinical trial of mesutoclax for the treatment of AML. Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, 'Mesutoclax is an important global asset of our company in the field of hematology. We are delighted to receive approval to initiate the clinical trial for the fourth indication of our BCL2 inhibitor. We will accelerate the clinical development of mesutoclax across multiple indications in China and globally to bring benefits to patients as early as possible.' About InnoCare InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. InnoCare Forward-looking Statements This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
Yahoo
19 minutes ago
- Business
- Yahoo
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China
BEIJING, May 29, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor mesutoclax (ICP-248) in combination with azacitidine for the treatment of myeloid malignancies, including but not limited to myelodysplastic syndromes (MDS). Mesutoclax is a novel, orally bioavailable BCL2 selective inhibitor. BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of various hematologic malignancies. Mesutoclax exerts anti-tumor activity by selectively inhibiting BCL2 and restoring the normal apoptosis process in cancer cells. Myelodysplastic syndrome (MDS) is a group of heterogeneous clonal myeloid diseases characterized by the abnormal proliferation of hematopoietic stem cells, recurrent genetic abnormalities, myelodysplasia, ineffective hematopoiesis, peripheral-blood cytopenia, and a high risk of progression to acute myeloid leukemia (AML). The annual incidence of myelodysplastic syndromes is about 4 cases/100,000 people/year (reaching 40–50/100,000 in patients aged ≥ 70 years). Mesutoclax has been granted Breakthrough Therapy Designation (BTD) by the CDE for the treatment of BTKi-treated relapsed or refractory mantle cell lymphoma (R/R MCL). This marks the first BCL2 inhibitor to receive BTD recognition in China. The Company is accelerating patient enrollment of a Phase III registrational trial of mesutoclax in combination with orelabrutinib as a first line therapy for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), as well as a clinical trial of mesutoclax for the treatment of AML. Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, "Mesutoclax is an important global asset of our company in the field of hematology. We are delighted to receive approval to initiate the clinical trial for the fourth indication of our BCL2 inhibitor. We will accelerate the clinical development of mesutoclax across multiple indications in China and globally to bring benefits to patients as early as possible." About InnoCare InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. InnoCare Forward-looking Statements This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance. View source version on Contacts Media Chunhua Investors 86-10-66609999ir@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
an hour ago
- Business
- Business Wire
EDOTCO and Sitetracker Partner to Digitally Transform Field Operations Across Asia
KUALA LUMPUR, Malaysia & MONTCLAIR, N.J.--(BUSINESS WIRE)--EDOTCO Group ('EDOTCO'), one of Asia's leading digital connectivity infrastructure companies, and Sitetracker, the global leader in full asset lifecycle management, today announced a strategic partnership to accelerate the digital transformation of EDOTCO's field operations across its regional footprint. "Our partnership with Sitetracker will enable us to standardize and modernize our field operations across the region." - Adlan Tajudin, Group Chief Executive Officer of EDOTCO This collaboration marks a major milestone in Asia's telecommunications infrastructure sector, with EDOTCO set to deploy Sitetracker's newly expanded Operations & Maintenance (O&M) platform across more than 55,000 towers in nine Asian markets - setting a new industry benchmark for operational scalability, efficiency and innovation. 'At EDOTCO, we are committed to building intelligent and resilient infrastructure that supports the future of digital connectivity,' said Adlan Tajudin, Group Chief Executive Officer of EDOTCO. 'Our partnership with Sitetracker will enable us to standardize and modernize our field operations across the region — empowering our teams with the tools to deliver greater service levels, operational agility, and data-driven decision-making at scale.' The Sitetracker platform will support EDOTCO in harmonizing field workflows, driving predictive maintenance, and unlocking operational visibility across its extensive tower infrastructure; transforming how preventive and corrective tasks are planned, executed, and tracked. Rewriting the Playbook for Field Operations and Maintenance EDOTCO's forward-looking strategy centers on developing a future-ready operations model that can respond to evolving digital demands across South and Southeast Asia. The deployment of the Sitetracker platform will empower EDOTCO to reduce complexity, eliminate manual interventions, and scale best-in-class O&M practices across diverse environments. Through this strategic alliance, EDOTCO will: Automate preventive and corrective maintenance - identifying potential issues early to ensure network reliability and reduce downtime; Streamline fleet and site asset audit workflows - eliminating process errors and facilitating more accurate inventory management and compliance; Enable secure, geo-tracked site check-in - enhancing workforce safety and accountability; Monitor Service Level Agreement (SLA) performance in real-time - improving service delivery and response; Integrate seamlessly with critical systems - eliminating data silos and aligning teams through a centralized, intelligent platform. 'EDOTCO's commitment to intelligent infrastructure management makes them an ideal partner,' said Giuseppe Incitti, CEO of Sitetracker. 'Their vision aligns perfectly with our mission to deliver best-in-class, end-to-end asset lifecycle management that empowers the world's most essential infrastructure.' Setting the Standard for a Digital-First Future With the roll-out of Sitetracker, EDOTCO will be among the first TowerCos in Asia to deploy a fully integrated, mobile O&M platform at this scale – further strengthening its commitment to innovation, sustainability, and operational resilience across the digital infrastructure value chain. This partnership represents a shared commitment by both companies to future-proof infrastructure management, streamline field execution, and enhance the quality of digital services across fast-growing markets in Southeast and South Asia. About Sitetracker Sitetracker empowers owners, operators, contractors, and other stakeholders to streamline and optimize the end-to-end asset lifecycle of critical infrastructure. As the leading global complete Asset Lifecycle Management platform, Sitetracker helps innovative companies like Vodafone, Ericsson, ENGIE, Telefonica, Cypress Creek Renewables, Cox, Iberdrola, EVgo, Vantage Towers, Southern Company, Zayo, Tilson, Nextera, EDOTCO, Axione, and TEP efficiently plan, build, operate, and maintain millions of projects, sites, and assets. Sitetracker delivers operational excellence and creates full transparency across industries such as digital infrastructure, renewables, EV charging, utilities, and real estate by driving safe, efficient teams, ensuring healthy projects, and enabling organizations to manage scale, growth, and complexity. Trusted by hundreds of industry leaders, Sitetracker advances a more connected and sustainable future across the world. Manage What's Critical, with Sitetracker. About EDOTCO Group Established in 2012, EDOTCO Group is the leading digital connectivity infrastructure services company in Asia, providing end-to-end integrated solutions in the tower services sector. Its mission is to help nations across Asia advance their connectivity infrastructure with leading-edge solutions and achieve equitable connectivity. With a portfolio of over 58,000 towers across nine countries, the company is present in Malaysia, Bangladesh, Philippines, Indonesia, Cambodia, Pakistan, Myanmar, Sri Lanka, and Laos - fulfilling connectivity demands innovatively and sustainably to help its customers and partners accelerate sustainable growth. EDOTCO prioritises prudent portfolio expansion for organic and inorganic opportunities that carry the right scale, economics, and returns for its shareholders. EDOTCO Group was named Asia Pacific Telecoms Tower Company of the Year for six consecutive years by Frost & Sullivan and was recognised as one of three ASEAN Unicorns based in Malaysia. For more information, visit
Yahoo
an hour ago
- Business
- Yahoo
EDOTCO and Sitetracker Partner to Digitally Transform Field Operations Across Asia
KUALA LUMPUR, Malaysia & MONTCLAIR, N.J., May 29, 2025--(BUSINESS WIRE)--EDOTCO Group ("EDOTCO"), one of Asia's leading digital connectivity infrastructure companies, and Sitetracker, the global leader in full asset lifecycle management, today announced a strategic partnership to accelerate the digital transformation of EDOTCO's field operations across its regional footprint. This collaboration marks a major milestone in Asia's telecommunications infrastructure sector, with EDOTCO set to deploy Sitetracker's newly expanded Operations & Maintenance (O&M) platform across more than 55,000 towers in nine Asian markets - setting a new industry benchmark for operational scalability, efficiency and innovation. "At EDOTCO, we are committed to building intelligent and resilient infrastructure that supports the future of digital connectivity," said Adlan Tajudin, Group Chief Executive Officer of EDOTCO. "Our partnership with Sitetracker will enable us to standardize and modernize our field operations across the region — empowering our teams with the tools to deliver greater service levels, operational agility, and data-driven decision-making at scale." The Sitetracker platform will support EDOTCO in harmonizing field workflows, driving predictive maintenance, and unlocking operational visibility across its extensive tower infrastructure; transforming how preventive and corrective tasks are planned, executed, and tracked. Rewriting the Playbook for Field Operations and Maintenance EDOTCO's forward-looking strategy centers on developing a future-ready operations model that can respond to evolving digital demands across South and Southeast Asia. The deployment of the Sitetracker platform will empower EDOTCO to reduce complexity, eliminate manual interventions, and scale best-in-class O&M practices across diverse environments. Through this strategic alliance, EDOTCO will: Automate preventive and corrective maintenance - identifying potential issues early to ensure network reliability and reduce downtime; Streamline fleet and site asset audit workflows - eliminating process errors and facilitating more accurate inventory management and compliance; Enable secure, geo-tracked site check-in - enhancing workforce safety and accountability; Monitor Service Level Agreement (SLA) performance in real-time - improving service delivery and response; Integrate seamlessly with critical systems - eliminating data silos and aligning teams through a centralized, intelligent platform. "EDOTCO's commitment to intelligent infrastructure management makes them an ideal partner," said Giuseppe Incitti, CEO of Sitetracker. "Their vision aligns perfectly with our mission to deliver best-in-class, end-to-end asset lifecycle management that empowers the world's most essential infrastructure." Setting the Standard for a Digital-First Future With the roll-out of Sitetracker, EDOTCO will be among the first TowerCos in Asia to deploy a fully integrated, mobile O&M platform at this scale – further strengthening its commitment to innovation, sustainability, and operational resilience across the digital infrastructure value chain. This partnership represents a shared commitment by both companies to future-proof infrastructure management, streamline field execution, and enhance the quality of digital services across fast-growing markets in Southeast and South Asia. About Sitetracker Sitetracker empowers owners, operators, contractors, and other stakeholders to streamline and optimize the end-to-end asset lifecycle of critical infrastructure. As the leading global complete Asset Lifecycle Management platform, Sitetracker helps innovative companies like Vodafone, Ericsson, ENGIE, Telefonica, Cypress Creek Renewables, Cox, Iberdrola, EVgo, Vantage Towers, Southern Company, Zayo, Tilson, Nextera, EDOTCO, Axione, and TEP efficiently plan, build, operate, and maintain millions of projects, sites, and assets. Sitetracker delivers operational excellence and creates full transparency across industries such as digital infrastructure, renewables, EV charging, utilities, and real estate by driving safe, efficient teams, ensuring healthy projects, and enabling organizations to manage scale, growth, and complexity. Trusted by hundreds of industry leaders, Sitetracker advances a more connected and sustainable future across the world. Manage What's Critical, with Sitetracker. About EDOTCO Group Established in 2012, EDOTCO Group is the leading digital connectivity infrastructure services company in Asia, providing end-to-end integrated solutions in the tower services sector. Its mission is to help nations across Asia advance their connectivity infrastructure with leading-edge solutions and achieve equitable connectivity. With a portfolio of over 58,000 towers across nine countries, the company is present in Malaysia, Bangladesh, Philippines, Indonesia, Cambodia, Pakistan, Myanmar, Sri Lanka, and Laos - fulfilling connectivity demands innovatively and sustainably to help its customers and partners accelerate sustainable growth. EDOTCO prioritises prudent portfolio expansion for organic and inorganic opportunities that carry the right scale, economics, and returns for its shareholders. EDOTCO Group was named Asia Pacific Telecoms Tower Company of the Year for six consecutive years by Frost & Sullivan and was recognised as one of three ASEAN Unicorns based in Malaysia. For more information, visit View source version on Contacts Media Contact Kathleen OjoSitetrackerpress@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Business
- Yahoo
Twenty High-Potential Startups Selected for MedTech Innovator's 2025 Asia Pacific Accelerator
Top medtech innovators from nine countries selected to join region's leading commercialization platform and compete for USD 300,000 in non-dilutive cash prizes and awards LOS ANGELES & SINGAPORE, May 29, 2025--(BUSINESS WIRE)--MedTech Innovator, the world's largest accelerator of medical technology companies, today announced that 20 high-potential medtech companies will participate in the sixth annual Asia Pacific (APAC) Accelerator program. "We're incredibly proud to welcome this diverse and dynamic group of startups to the 2025 Asia Pacific Accelerator Program," said Fredrik Nyberg, managing director, MedTech Innovator Asia Pacific. "This year's cohort is tackling some of the most pressing challenges in healthcare with bold ideas and transformative technologies. We're excited to support their journey, connect them with key industry partners, and accelerate their path to market, ultimately improving patient outcomes across APAC and globally." MedTech Innovator Asia Pacific unites best-in-class startups with investors, business leaders, and allied service professionals in the medtech industry to help drive the commercialization of life-changing technologies in the region. The 2025 cohort companies will also compete for up to USD 300,000 in non-dilutive cash prizes and awards. More than 550 companies applied for the Asia Pacific program this year, and after a rigorous selection process, 60 companies were invited to pitch, 20 of which were named to the 2025 cohort. The Asia Pacific Accelerator 2025 Cohort will attend the program's kick-off, joining the MedTech Innovator and the BioTools Innovator 2025 Cohorts at the invitation-only Innovator Summit on June 25-26 in Mountain View, California. This event connects the leadership teams from the latest cohorts with MedTech Innovator's partners, alumni, and other industry leaders. The 20 companies selected for the 2025 MedTech Innovator Asia Pacific Accelerator are: 2Strands Biosciences, Singapore Australis Scientific, Brisbane, Australia Belun Technology, Singapore B dot Medical, Tokyo, Japan Borns Medical Robotics Inc., San Jose, California, United States ClearCut Medical, Rehovot, Israel Fukuoka, Japan Hemotag, Boca Raton, Florida, United States Heuron Co., Seoul, South Korea HiCura Medical, Singapore Laronix, Brisbane, Australia MAXM Skate, Adelaide, Australia MEDICAL IP, Seoul, South Korea MedInTech Inc., Seoul, South Korea OsseoLabs, Bangkok, Thailand Pretect Devices, Perth, Australia Rosalind Dx, Singapore Sehat Kahani, Karachi, Pakistan SIMPLEX QUANTUM, Tokyo, Japan VesselSens, Bonn, Germany MedTech Innovator Asia Pacific's 2025 program sponsors include Johnson & Johnson MedTech, B. Braun Medical, Becton Dickinson, Teleflex, Siemens Healthineers, Cambridge Consultants, and Enterprise Singapore. The program will culminate with its first-ever self-hosted Showcase and Grand Finals in Singapore at the end of October. About MedTech Innovator MedTech Innovator is the world's largest accelerator of medical technology companies. Its mission is to improve human health by accelerating the growth of companies that are transforming care. MedTech Innovator has been a catalyst for groundbreaking healthcare solutions, reviewing well over 14,000 applicants and fostering the growth of 717 companies globally that have collectively raised over USD 9.5 billion in follow-on funding, transforming the lives of millions. For more information about MedTech Innovator Asia Pacific, its annual programs, portfolio of industry-leading startups, and insights on trends, visit MedTech Innovator Asia Pacific's website, follow the U.S. organization on LinkedIn U.S. and its APAC program at LinkedIn APAC, and subscribe to its monthly newsletter. View source version on Contacts Media Contact Bernice TanMarketing & Events Manager, Asia Pacificbernice@ Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
